Scilex (SCLX) Competitors

Scilex (NASDAQ:SCLX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Does the media favor SCLX or CADL?

In the previous week, Candel Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Scilex. Scilex's average media sentiment score of 0.85 beat Candel Therapeutics' score of 0.64 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor SCLX or CADL?

Candel Therapeutics received 4 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 66.67% of users gave Candel Therapeutics an outperform vote.

Company	Underperform	Outperform
Scilex	Outperform Votes 12 100.00%	Underperform Votes No Votes
Candel Therapeutics	Outperform Votes 16 66.67%	Underperform Votes 8 33.33%

Which has more risk and volatility, SCLX or CADL?

Scilex has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -1.29, indicating that its share price is 229% less volatile than the S&P 500.

Is SCLX or CADL more profitable?

Candel Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -159.10%. Scilex's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-159.10%	N/A	-93.65%
Candel Therapeutics	N/A	-629.29%	-173.39%

Do analysts rate SCLX or CADL?

Scilex presently has a consensus target price of $14.00, indicating a potential upside of 5,857.45%. Candel Therapeutics has a consensus target price of $21.00, indicating a potential upside of 243.14%. Given Scilex's higher probable upside, research analysts clearly believe Scilex is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Candel Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has preferable earnings and valuation, SCLX or CADL?

Candel Therapeutics has lower revenue, but higher earnings than Scilex. Candel Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$55.15M	1.04	-$114.33M	-$0.83	-0.28
Candel Therapeutics	$120K	2,408.99	-$37.94M	-$1.75	-3.50

Do insiders & institutionals have more ownership in SCLX or CADL?

69.7% of Scilex shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 7.7% of Scilex shares are held by insiders. Comparatively, 41.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Scilex beats Candel Therapeutics on 10 of the 16 factors compared between the two stocks.